Prebiotic Fiber as a Modifier of Satiety Hormones and Body Weight in Overweight and Obese Adults
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine if oligofructose supplementation promotes weight loss in overweight and obese adults.
| Condition | Intervention |
|---|---|
|
Obesity |
Dietary Supplement: Oligofructose Dietary Supplement: Placebo |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Effect of Oligofructose Versus Placebo on Body Weight and Satiety Hormone Secretion in Overweight and Obese Adults. |
- Body weight [ Time Frame: 3 months ] [ Designated as safety issue: No ]
- Plasma satiety hormones [ Time Frame: 3 months ] [ Designated as safety issue: No ]
| Enrollment: | 48 |
| Study Start Date: | January 2007 |
| Study Completion Date: | August 2007 |
| Primary Completion Date: | May 2007 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: 1
Oligofructose
|
Dietary Supplement: Oligofructose
21 grams per day in distributed over 3 doses per day for 3 months
Other Name: Raftilose P95
|
|
Placebo Comparator: 2
Placebo
|
Dietary Supplement: Placebo
7.89 grams of placebo maltodextrin divided into 3 equal doses per day for 3 months
Other Name: Maltrin M100
|
Detailed Description:
Obesity is a primary health concern for many western countries as it is linked to several chronic diseases as well as, large health care costs. Although obesity is a multifactorial disease, it is known that levels of satiety hormones including glucagon like peptide-1 (GLP-1) and peptide YY (PYY) are reduced in obesity. The ability of prebiotic fiber to promote weight loss through the production of satiety hormones has been tested previously using rodents. Here it was found that prebiotic supplementation resulted in a decreased energy intake, higher GLP-1 levels in the plasma and increased proglucagon mRNA levels in the gut. This study will address the important question of whether prebiotic fiber supplementation is effective in reducing body weight in overweight or obese human subjects.
Eligibility| Ages Eligible for Study: | 20 Years to 70 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- overweight or class I obese individuals with BMI between 25 kg/m2 and 34.9 kg/m2
- stable body weight in previous 3 months
Exclusion Criteria:
- Type 1 and Type 2 diabetes
- clinically significant cardiovascular abnormalities
- liver or pancreas disease
- major gastrointestinal surgeries
- are pregnant or lactating
- exhibit alcohol or drug dependence
- on drugs influencing appetite
- are following a diet or exercise regime designed for weight loss
- have a body mass greater than 350lb
- chronic use of antacids or bulk laxatives
Contacts and Locations| Canada, Alberta | |
| Faculty of Kinesiology, Roger Jackson Centre for Health and Wellness Research | |
| Calgary, Alberta, Canada, T2N 1N4 | |
| Principal Investigator: | Raylene A. Reimer, PhD, RD | University of Calgary |
More Information
No publications provided by University of Calgary
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Raylene Reimer, Associate Professor, University of Calgary |
| ClinicalTrials.gov Identifier: | NCT00522353 History of Changes |
| Other Study ID Numbers: | UC 20085 |
| Study First Received: | August 27, 2007 |
| Last Updated: | May 21, 2008 |
| Health Authority: | Canada: Health Canada |
Keywords provided by University of Calgary:
|
obesity weight loss satiety hormones body composition appetite ratings |
Additional relevant MeSH terms:
|
Body Weight Obesity Overweight Signs and Symptoms Overnutrition |
Nutrition Disorders Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Pharmacologic Actions |
ClinicalTrials.gov processed this record on June 17, 2013